BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34381563)

  • 21. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
    Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
    PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma.
    Zhang B; Cheng B; Li FS; Ding JH; Feng YY; Zhuo GZ; Wei HF; Zhao K
    Tumour Biol; 2015 Dec; 36(12):9411-9. PubMed ID: 26113408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
    Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer.
    van Rhijn BW
    Urol Oncol; 2012; 30(4):518-23. PubMed ID: 22742564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73) in pig aortic valves.
    Kaniewska E; Sielicka A; Sarathchandra P; Pelikant-Małecka I; Olkowicz M; Słomińska EM; Chester AH; Yacoub MH; Smoleński RT
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):305-12. PubMed ID: 24940684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Prognostic Biomarker of Luminal Breast Cancer: High CD39 Expression Is Related to Poor Survival.
    Ni X; Wan W; Ma J; Liu X; Zheng B; He Z; Yang W; Huang L
    Front Genet; 2021; 12():682503. PubMed ID: 34220957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
    Häusler SF; Del Barrio IM; Diessner J; Stein RG; Strohschein J; Hönig A; Dietl J; Wischhusen J
    Am J Transl Res; 2014; 6(2):129-39. PubMed ID: 24489992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
    Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
    Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.
    Wettstein MS; Buser L; Hermanns T; Roudnicky F; Eberli D; Baumeister P; Sulser T; Wild P; Poyet C
    Dis Markers; 2015; 2015():785461. PubMed ID: 26543299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
    Festag J; Thelemann T; Schell M; Raith S; Michel S; Jaschinski F; Klar R
    Mol Ther Nucleic Acids; 2020 Sep; 21():656-669. PubMed ID: 32739778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 1α, 25-Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells.
    Bagatini MD; Bertolin K; Bridi A; Pelinson LP; da Silva Rosa Bonadiman B; Pillat MM; Gonçalves PBD; Ulrich H; Schetinger MRC; Morsch VM
    J Cell Biochem; 2019 Jun; 120(6):9992-10000. PubMed ID: 30548323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracellular ATP inhibits IL-1-induced MMP-1 expression through the action of CD39/nucleotidase triphosphate dephosphorylase-1 on human gingival fibroblasts.
    Nemoto E; Gotoh K; Tsuchiya M; Sakisaka Y; Shimauchi H
    Int Immunopharmacol; 2013 Nov; 17(3):513-8. PubMed ID: 23941770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer.
    Koivisto MK; Tervahartiala M; Kenessey I; Jalkanen S; Boström PJ; Salmi M
    Carcinogenesis; 2019 Mar; 40(1):84-92. PubMed ID: 30395172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
    Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
    Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purinergic signaling during intestinal inflammation.
    Longhi MS; Moss A; Jiang ZG; Robson SC
    J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
    Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
    Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ectonucleotidase CD39 expression in regional metastases in head and neck cancer.
    Mandapathil M; Boduc M; Roessler M; Güldner C; Walliczek-Dworschak U; Mandic R
    Acta Otolaryngol; 2018 Apr; 138(4):428-432. PubMed ID: 29172836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.